{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:49:05Z","timestamp":1794815345549,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"LamKap Bio alpha"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>T-cell retargeting to eliminate CEACAM5-expressing cancer cells via CEACAM5xCD3 bispecific antibodies (BsAbs) showed limited clinical activity so far, mostly due to insufficient T-cell activation, dose-limiting toxicities, and formation of anti-drug antibodies (ADA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We present here the generation and preclinical development of NILK-2301, a BsAb composed of a common heavy chain and two different light chains, one kappa and one lambda, determining specificity (so-called \u03ba\u03bb body format).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>NILK-2301 binds CD3\u025b on T-cells with its lambda light chain arm with an affinity of \u2248100\u00a0nM, and the CEACAM5 A2 domain on tumor cells by its kappa light chain arm with an affinity of \u22485\u00a0nM. Fc\u03b3R-binding is abrogated by the \u201cLALAPA\u201d mutation (Leu234Ala, Leu235Ala, Pro329Ala). NILK-2301 induced T-cell activation, proliferation, cytokine release, and T-cell dependent cellular cytotoxicity of CEACAM5-positive tumor cell lines (5\/5 colorectal, 2\/2 gastric, 2\/2 lung), e.g., SK-CO-1 (<jats:italic>E<\/jats:italic><jats:sub>max<\/jats:sub>\u2009=\u200989%), MKN-45 (<jats:italic>E<\/jats:italic><jats:sub>max<\/jats:sub>\u2009=\u200984%), and H2122 (<jats:italic>E<\/jats:italic><jats:sub>max<\/jats:sub>\u2009=\u200997%), with EC<jats:sub>50<\/jats:sub> ranging from 0.02 to 0.14\u00a0nM. NILK-2301 binds neither to CEACAM5-negative or primary colon epithelial cells nor to other CEACAM family members. NILK-2301 alone or in combination with checkpoint inhibition showed activity in organotypic tumor tissue slices and colorectal cancer organoid models. In vivo, NILK-2301 at 10\u00a0mg\/kg significantly delayed tumor progression in colon- and a pancreatic adenocarcinoma model. Single-dose pharmacokinetics (PK) and tolerability in cynomolgus monkeys at 0.5 or 10\u00a0mg\/kg intravenously or 20\u00a0mg subcutaneously showed dose-proportional PK, bioavailability \u2248100%, and a projected half-life in humans of 13.1\u00a0days. NILK-2301 was well-tolerated. Data were confirmed in human FcRn TG32 mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In summary, NILK-2301 combines promising preclinical activity and safety with lower probability of ADA-generation due to its format compared to other molecules and is scheduled to enter clinical testing at the end of 2023.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-023-01516-3","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T13:02:56Z","timestamp":1702386176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Development and characterization of NILK-2301, a novel CEACAM5xCD3 \u03ba\u03bb bispecific antibody for immunotherapy of CEACAM5-expressing cancers"],"prefix":"10.1186","volume":"16","author":[{"given":"Anja","family":"Seckinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Majocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ry","family":"Moine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Nouveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang","family":"Ngoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Daubeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Ravn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Pleche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Calloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Broyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Lesnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Chatel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Salgado-Pires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Gockel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Masternak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Poitevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Magistrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Malinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Kallendrusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Strein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"issue":"6","key":"1516_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc3930","volume":"15","author":"GJ Weiner","year":"2015","unstructured":"Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361\u201370.","journal-title":"Nat Rev Cancer"},{"issue":"6230","key":"1516_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56\u201361.","journal-title":"Science"},{"issue":"1","key":"1516_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12527","volume":"276","author":"HL Matlung","year":"2017","unstructured":"Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276(1):145\u201364.","journal-title":"Immunol Rev"},{"issue":"1","key":"1516_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","volume":"16","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo A, \u00c1lvarez-Vallina L, Sanz L. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol. 2023;16(1):83.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1516_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3390\/biomedicines10030655","volume":"10","author":"P Guha","year":"2022","unstructured":"Guha P, Heatherton KR, O\u2019Connell KP, Alexander IS, Katz SC. Assessing the future of solid tumor immunotherapy. Biomedicines. 2022;10(3):655.","journal-title":"Biomedicines"},{"issue":"1","key":"1516_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-023-00372-8","volume":"12","author":"W Ma","year":"2023","unstructured":"Ma W, Xue R, Zhu Z, et al. Increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol. 2023;12(1):10.","journal-title":"Exp Hematol Oncol"},{"key":"1516_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1188049.","journal-title":"Front Immunol"},{"issue":"19","key":"1516_CR8","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.3390\/cells11193147","volume":"11","author":"A Mendoza-Valderrey","year":"2022","unstructured":"Mendoza-Valderrey A, Alvarez M, De Maria A, Margolin K, Melero I, Ascierto ML. Next generation immuno-oncology strategies: unleashing NK cells activity. Cells. 2022;11(19):3147.","journal-title":"Cells"},{"key":"1516_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/B978-012088451-3.50016-8","volume-title":"T cell activation. The immune response","author":"TWaS Mak","year":"2006","unstructured":"Mak TWaS, Mary E. T cell activation. The immune response. London: Academic Press; 2006. p. 373\u2013401."},{"key":"1516_CR10","doi-asserted-by":"crossref","unstructured":"Mir MA. Chapter 1 - Introduction to Costimulation and Costimulatory Molecules. In: Mir MA, ed. Developing costimulatory molecules for immunotherapy of diseases: academic press; 2015:1\u201343.","DOI":"10.1016\/B978-0-12-802585-7.00001-7"},{"issue":"1","key":"1516_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2018","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2018;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"8","key":"1516_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"7","key":"1516_CR13","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2021","unstructured":"Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2021;386(7):640\u201354.","journal-title":"N Engl J Med"},{"issue":"6","key":"1516_CR14","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265\u201374.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1516_CR15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","volume":"31","author":"A Seckinger","year":"2017","unstructured":"Seckinger A, Delgado JA, Moser S, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31(3):396\u2013410.","journal-title":"Cancer Cell"},{"issue":"Supplement 1","key":"1516_CR16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1182\/blood-2022-159009","volume":"140","author":"SW Wong","year":"2022","unstructured":"Wong SW, Bar N, Paris L, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study. Blood. 2022;140(Supplement 1):400\u20132.","journal-title":"Blood"},{"issue":"10301","key":"1516_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665\u201374.","journal-title":"Lancet"},{"issue":"18","key":"1516_CR18","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a Phase I Trial. J Clin Oncol. 2021;39(18):1959\u201370.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1516_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1084\/jem.122.3.467","volume":"122","author":"P Gold","year":"1965","unstructured":"Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965;122(3):467\u201381.","journal-title":"J Exp Med"},{"key":"1516_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1084\/jem.121.3.439","volume":"121","author":"P Gold","year":"1965","unstructured":"Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965;121:439\u201362.","journal-title":"J Exp Med"},{"issue":"3\u20134","key":"1516_CR21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","volume":"32","author":"N Beauchemin","year":"2013","unstructured":"Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32(3\u20134):643\u201371.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"1516_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.bbrc.2005.05.084","volume":"333","author":"Y Yamamoto","year":"2005","unstructured":"Yamamoto Y, Hirakawa E, Mori S, Hamada Y, Kawaguchi N, Matsuura N. Cleavage of carcinoembryonic antigen induces metastatic potential in colorectal carcinoma. Biochem Biophys Res Commun. 2005;333(1):223\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1516_CR23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1172\/JCI113636","volume":"82","author":"TL Sack","year":"1988","unstructured":"Sack TL, Gum JR, Low MG, Kim YS. Release of carcinoembryonic antigen from human colon cancer cells by phosphatidylinositol-specific phospholipase C. J Clin Investig. 1988;82(2):586\u201393.","journal-title":"J Clin Investig"},{"issue":"2","key":"1516_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.canlet.2005.03.028","volume":"234","author":"F Naghibalhossaini","year":"2006","unstructured":"Naghibalhossaini F, Ebadi P. Evidence for CEA release from human colon cancer cells by an endogenous GPI-PLD enzyme. Cancer Lett. 2006;234(2):158\u201367.","journal-title":"Cancer Lett"},{"issue":"4","key":"1516_CR25","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1007\/s11033-011-1144-0","volume":"39","author":"A Pakdel","year":"2012","unstructured":"Pakdel A, Naghibalhossaini F, Mokarram P, Jaberipour M, Hosseini A. Regulation of carcinoembryonic antigen release from colorectal cancer cells. Mol Biol Rep. 2012;39(4):3695\u2013704.","journal-title":"Mol Biol Rep"},{"issue":"2","key":"1516_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1006\/scbi.1998.0119","volume":"9","author":"S Hammarstrom","year":"1999","unstructured":"Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9(2):67\u201381.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"1516_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ceb.2006.08.008","volume":"18","author":"K Kuespert","year":"2006","unstructured":"Kuespert K, Pils S, Hauck CR. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol. 2006;18(5):565\u201371.","journal-title":"Curr Opin Cell Biol"},{"issue":"13","key":"1516_CR28","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-15-1696","volume":"22","author":"M Bacac","year":"2016","unstructured":"Bacac M, Fauti T, Sam J, et al. A novel carcinoembryonic antigen T-Cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016;22(13):3286\u201397.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1516_CR29","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.4161\/19420862.2014.975660","volume":"6","author":"MD Oberst","year":"2014","unstructured":"Oberst MD, Fuhrmann S, Mulgrew K, et al. CEA\/CD3 bispecific antibody MEDI-565\/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs. 2014;6(6):1571\u201384.","journal-title":"MAbs"},{"issue":"4","key":"1516_CR30","first-page":"847","volume":"49","author":"D Boucher","year":"1989","unstructured":"Boucher D, Cournoyer D, Stanners CP, Fuks A. Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue. Cancer Res. 1989;49(4):847\u201352.","journal-title":"Cancer Res"},{"issue":"24","key":"1516_CR31","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","volume":"26","author":"S Decary","year":"2020","unstructured":"Decary S, Berne PF, Nicolazzi C, et al. Preclinical activity of SAR408701: a novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors. Clin Cancer Res. 2020;26(24):6589\u201399.","journal-title":"Clin Cancer Res"},{"issue":"27","key":"1516_CR32","doi-asserted-by":"publisher","first-page":"6763","DOI":"10.1200\/JCO.2005.18.622","volume":"23","author":"T Liersch","year":"2005","unstructured":"Liersch T, Meller J, Kulle B, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol. 2005;23(27):6763\u201370.","journal-title":"J Clin Oncol"},{"issue":"29","key":"1516_CR33","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","volume":"35","author":"E Dotan","year":"2017","unstructured":"Dotan E, Cohen SJ, Starodub AN, et al. Phase I\/II Trial of Labetuzumab Govitecan (Anti-CEACAM5\/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J Clin Oncol. 2017;35(29):3338\u201346.","journal-title":"J Clin Oncol"},{"key":"1516_CR34","doi-asserted-by":"crossref","unstructured":"Tabernero J, Melero I, Ros W, et al. Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 2017;35(15_suppl):3002\u20133002.","DOI":"10.1200\/JCO.2017.35.15_suppl.3002"},{"issue":"4","key":"1516_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.clcc.2016.07.009","volume":"15","author":"M Pishvaian","year":"2016","unstructured":"Pishvaian M, Morse MA, McDevitt J, et al. Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen, in patients with advanced gastrointestinal adenocarcinomas. Clin Colorectal Cancer. 2016;15(4):345\u201351.","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"1516_CR36","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","volume":"33","author":"A Gazzah","year":"2022","unstructured":"Gazzah A, Bedard PL, Hierro C, et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody\u2013drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022;33(4):416\u201325.","journal-title":"Ann Oncol"},{"key":"1516_CR37","first-page":"viii139","volume":"29","author":"KL Moek","year":"2018","unstructured":"Moek KL, Fiedler WM, von Einem JC, et al. Phase I study of AMG 211\/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed\/refractory gastrointestinal (GI) adenocarcinoma. Ann Oncol. 2018;29:viii139\u201340.","journal-title":"Ann Oncol"},{"key":"1516_CR38","unstructured":"NCT03539484. A study of RO7172508 in patients with locally advanced and\/or metastatic CEA-Positive solid tumors. 2018;2023. https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT03539484?cond=RO7172508&draw=2&rank=1"},{"key":"1516_CR39","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1038\/ncomms7113","volume":"6","author":"N Fischer","year":"2015","unstructured":"Fischer N, Elson G, Magistrelli G, et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun. 2015;6:6113.","journal-title":"Nat Commun"},{"issue":"2","key":"1516_CR40","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1080\/19420862.2018.1558698","volume":"11","author":"E Hatterer","year":"2019","unstructured":"Hatterer E, Barba L, Noraz N, et al. Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor\/CD19 association leading to impaired B-cell proliferation. MAbs. 2019;11(2):322\u201334.","journal-title":"MAbs"},{"issue":"8","key":"1516_CR41","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/eji.202149181","volume":"51","author":"L Nouveau","year":"2021","unstructured":"Nouveau L, Buatois V, Cons L, et al. Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies. Eur J Immunol. 2021;51(8):2074\u201385.","journal-title":"Eur J Immunol"},{"issue":"2","key":"1516_CR42","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1016\/j.clcc.2017.11.002","volume":"17","author":"R Sonnichsen","year":"2018","unstructured":"Sonnichsen R, Hennig L, Blaschke V, et al. Individual susceptibility analysis using patient-derived slice cultures of colorectal carcinoma. Clin Colorectal Cancer. 2018;17(2):e189\u201399.","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"1516_CR43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/j.1460-2075.1985.tb03634.x","volume":"4","author":"S Pessano","year":"1985","unstructured":"Pessano S, Oettgen H, Bhan AK, Terhorst C. The T3\/T cell receptor complex: antigenic distinction between the two 20-kd T3 (T3-delta and T3-epsilon) subunits. EMBO J. 1985;4(2):337\u201344.","journal-title":"EMBO J"},{"issue":"1\u20132","key":"1516_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/08830189709045703","volume":"16","author":"A Tamm","year":"1997","unstructured":"Tamm A, Schmidt RE. IgG binding sites on human Fc gamma receptors. Int Rev Immunol. 1997;16(1\u20132):57\u201385.","journal-title":"Int Rev Immunol"},{"issue":"1","key":"1516_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0161-5890(92)90156-R","volume":"29","author":"J Lund","year":"1992","unstructured":"Lund J, Pound JD, Jones PT, et al. Multiple binding sites on the CH2 domain of IgG for mouse Fc gamma R11. Mol Immunol. 1992;29(1):53\u20139.","journal-title":"Mol Immunol"},{"issue":"9","key":"1516_CR46","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1074\/jbc.M009483200","volume":"276","author":"RL Shields","year":"2001","unstructured":"Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276(9):6591\u2013604.","journal-title":"J Biol Chem"},{"issue":"2","key":"1516_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.vascn.2012.12.003","volume":"68","author":"L Bailey","year":"2013","unstructured":"Bailey L, Moreno L, Manigold T, et al. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies. J Pharmacol Toxicol Methods. 2013;68(2):231\u20139.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"6","key":"1516_CR48","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/19420862.2016.1193660","volume":"8","author":"LB Avery","year":"2016","unstructured":"Avery LB, Wang M, Kavosi MS, et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs. 2016;8(6):1064\u201378.","journal-title":"MAbs"},{"key":"1516_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00896-4","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Pang Y, Ji J, et al. Harnessing 3D in vitro systems to model immune responses to solid tumours: a step towards improving and creating personalized immunotherapies. Nat Rev Immunol. 2023. https:\/\/doi.org\/10.1038\/s41577-023-00896-4.","journal-title":"Nat Rev Immunol"},{"issue":"23","key":"1516_CR50","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu K-K, Kim TW, et al. Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318.","journal-title":"N Engl J Med"},{"issue":"1","key":"1516_CR51","doi-asserted-by":"publisher","first-page":"1960729","DOI":"10.1080\/2162402X.2021.1960729","volume":"10","author":"M Husstegge","year":"2021","unstructured":"Husstegge M, Hoang NA, Rebstock J, et al. PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. Oncoimmunology. 2021;10(1):1960729.","journal-title":"Oncoimmunology"},{"key":"1516_CR52","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1741-7007-8-12","volume":"8","author":"R Kammerer","year":"2010","unstructured":"Kammerer R, Zimmermann W. Coevolution of activating and inhibitory receptors within mammalian carcinoembryonic antigen families. BMC Biol. 2010;8:12.","journal-title":"BMC Biol"},{"issue":"7","key":"1516_CR53","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/CJI.0000000000000132","volume":"39","author":"S Dudal","year":"2016","unstructured":"Dudal S, Hinton H, Giusti AM, et al. Application of a MABEL approach for a T-cell-bispecific monoclonal antibody: CEA TCB. J Immunother. 2016;39(7):279\u201389.","journal-title":"J Immunother"},{"issue":"8","key":"1516_CR54","doi-asserted-by":"publisher","first-page":"e1203498","DOI":"10.1080\/2162402X.2016.1203498","volume":"5","author":"M Bacac","year":"2016","unstructured":"Bacac M, Klein C, Umana P. CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. OncoImmunology. 2016;5(8):e1203498.","journal-title":"OncoImmunology"},{"key":"1516_CR55","doi-asserted-by":"crossref","unstructured":"Melero I, Segal NH, Suarez JMS, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA CD3 TCB) for the treatment of CEA-expressing solid tumors. J Clinical Oncology. 2017;35(15_suppl):2549\u20132549.","DOI":"10.1200\/JCO.2017.35.15_suppl.2549"},{"key":"1516_CR56","unstructured":"Choudary S, Parupudi A (Medimmune LLC). Formulations of bispecific antibodies; patent application PCT\/US2015\/047843 (WO2016036678A1); 2015."},{"issue":"1","key":"1516_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14(1):75.","journal-title":"J Hematol Oncol"},{"issue":"Supplement 1","key":"1516_CR58","doi-asserted-by":"publisher","first-page":"6599","DOI":"10.1182\/blood-2022-169171","volume":"140","author":"E Hawkes","year":"2022","unstructured":"Hawkes E, Lewis KL, Wong Doo N, et al. First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19\/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma. Blood. 2022;140(Supplement 1):6599\u2013601.","journal-title":"Blood"},{"issue":"Suppl 2","key":"1516_CR59","first-page":"A740","volume":"10","author":"E Romano","year":"2022","unstructured":"Romano E, Medioni J, Rouge TDLM, et al. 707 A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers. J Immunother Cancer. 2022;10(Suppl 2):A740\u2013A740.","journal-title":"J Immunother Cancer"},{"issue":"496","key":"1516_CR60","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1126\/scitranslmed.aav5989","volume":"11","author":"C Claus","year":"2019","unstructured":"Claus C, Ferrara C, Xu W, et al. Tumor-targeted 4\u20131BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci Transl Med. 2019;11(496):989.","journal-title":"Sci Transl Med"},{"key":"1516_CR61","doi-asserted-by":"crossref","unstructured":"Seckinger AaM, Moine V, Nouveau L, Daubeuf B, Buatois V, Gueneau F, Ravn U, Masternak K, Poitevin Y, Magistrelli G, Malinge P, Shang L, Fischer N, Strein K, Ferlin WG, Hose D. Novel CEAxCD3 (NILK-2301) and CEAxCD28 (NILK-3301) kl bispecific antibodies for next generation immunotherapy of CEA-expressing cancer. ESMO Congress 2022. Ann. Oncol. 2022;33, S888.","DOI":"10.1016\/j.annonc.2022.07.878"},{"issue":"525","key":"1516_CR62","doi-asserted-by":"publisher","first-page":"7888","DOI":"10.1126\/scitranslmed.aaw7888","volume":"12","author":"D Skokos","year":"2020","unstructured":"Skokos D, Waite JC, Haber L, et al. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. Sci Transl Medine. 2020;12(525):7888.","journal-title":"Sci Transl Medine."},{"issue":"Suppl 2","key":"1516_CR63","first-page":"A892","volume":"10","author":"A Seckinger","year":"2022","unstructured":"Seckinger A, Buatois V, Moine V, et al. Novel CEAxCD47 (NILK-2401) and CEAxCD3 (NILK-2301) kl bispecific antibodies for multimodal immunotherapy of CEA-expressing solid cancer. J Immunother Cancer. 2022;10(Suppl 2):A892\u2013A892.","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01516-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01516-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01516-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T13:05:05Z","timestamp":1702386305000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01516-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01516-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"19 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.S. and D.H. declare employment at LamKap Bio Group. S.M., V.M., L.N., B.D., U.R., N.P., S.C., L.B., L.C., A.L., L.Ch., A.P., K.M., Y.P., G.M., P.M., and L.S. declare employment at Light Chain Bioscience\u2014Novimmune SA. S.S.P. declares consultancy work for Light Chain Bioscience\u2014Novimmune SA and LamKap Bio. A.S., K.S., and D.H. hold shares of LamKap Bio. S.K. declares research funding from LamKap Bio. S.Kr. received fees for lectures of MSD Sharp & Dohme GmbH and collaborates with Johnson&Johnson GmbH. F.L. received fees for lectures, expert appraisal or consulting services from Amgen GmbH, Astellas Pharma GmbH, AstraZeneca GmbH, Bayer AG, BioNTech SE, Bristol-Myers Squibb GmbH & Co. KGaA, Daiichi Sankyo Deutschland GmbH, Lilly Deutschland GmbH, Elsevier GmbH, Falk Foundation e.V., Incyte Inc, Merck KGaA, MSD Sharp & Dohme GmbH, Novartis Pharma GmbH, Roche Deutschland Holding GmbH, Servier Deutschland GmbH, Springe Nature AG & Co. KGaA, StreamedUp! GmbH; research projects are supported by Bristol-Myers Squibb GmbH und Co. KGaA and Gilead Science GmbH. H.N. and I.G. declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}